Clinical efficacy of transurethral plasmakinetic resection of bladder tumor combined with gemcitabine intravesical chemotherapy for superficial bladder cancer
SHI Yang
HUANG Liuhu
Abstract：Objective To evaluate the clinical efficacy of transurethral plasmakinetic resection of bladder tumor combined with gemcitabine intravesical chemotherapy for patients with superficial bladder cancer.Methods A total of 87 patients with superficial bladder cancer admitted to Rugao People's Hospital from January 2019 to March 2023 were randomly divided into a treatment group and a control group.The treatment group(44 patients)received gemcitabine bladder perfusion chemotherapy after transurethral plasmakinetic resection of bladder tumor,while the control group(43 patients)only underwent transurethral resection of the bladder tumor.There was no statistically significant difference between the two groups in terms of gender composition,age,pathological grading,staging,and underlying diseases(P＞0.05).The treatment effect,recurrence situations,and levels of tumor markers and serum markers before and after treatment were compared between the two groups,and the occurrence of adverse reactions was recorded.Results All the surgeries were successful at one time,and the tumor size was between 0.5-3.0 cm,and the average diameter was 1.6 cm.The average operation time was 23 min,and the blood loss was less than 10 mL.The recurrence rates in the treatment group at 3,6,and 12 months post-surgery were lower than those in the control group,and the rates of complete and partial remission were higher than those in the control group,but the differences were not statistically significant(P＞0.05).Similarly,urinary tumor markers(CYFR21-1,NMP22,BTA)in the treatment group were significantly lower than those before treatment,and the improvement was more significant than those in the control group(P＜0.05).Additionally,levels of VEGFC and VEGFA in the treatment group were also significantly reduced post-treatment,and the incidence of adverse reactions in the treatment group was significantly lower than those in the control group(P＜0.05).Conclusions Transurethral plasmakinetic resection of bladder tumor combined with gemcitabine intravesical chemotherapy can reduce the level tumor markers in patients and prevent the occurrence of adverse reactions.
Keywords：Superficial bladder cancerTransurethral plasmakinetic resection of bladder tumorGemcitabineRecurrence rate
Publication Date：2024-10-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 475-479 )